Summary
Introduction
Propranolol has been reported to decrease portal venous pressure [l] and to prevent the recurrence of gastrointestinal bleeding in cirrhotic patients [2] . Accordingly, the drug may become increasingly used in these patients. In patients with cirrhosis, the oxidative metabolism of drugs in the liver is markedly reduced [3] . Propranolol control subjects will also inhibit it in cirrhotic patients. Indeed, cimetidine, albeit decreasing the clearance of antipyrine in control subjects, did not decrease it in cirrhotic patients [6] .
We have measured the clearance of antipyrine before, and during, the administration of propranolol in eight cirrhotic patients.
Methods
We studied eight male patients (age 33-63 years) with biopsy-proven alcoholic cirrhosis, who were hospitalized for a recent episode of gastrointestinal bleeding. The criteria for inclusion and the overall protocol were identical with those previously reported [l, 21 and approved by the Cornit6 d'Ethique de 1'Institut National de la Santt? et de la Recherche Mbdicale [2] . Two weeks after the cessation of haemorrhage and the withdrawal of any drug, blood was drawn for liver-function tests, and antipyrine (15 mg/kg) was administered intravenously; blood was drawn 3, 6, 9, 12 and 24 h later and the concentration of antipyrine in plasma was determined by the method of Brodie et al. [7] . The day after the administration of antipyrine, an hepatic vein was catheterized, a n d ' pressures were recorded. The cardiac output was determined by the thermodilution method [8] ; liver blood flow was determined by the constant indocyanine green perfusion technique [9] . The following day, the patients were started on propranolol, given by mouth, at 08.00 and 20.00 hours, in progressively increasing doses until the resting heart rate was decreased by about 25%; the patients were then discharged. They received no other drug and claimed to have been abstinent for the whole period between the two studies. After 1 month of propranolol therapy, the various procedures were repeated, while the administration of propranolol was continued; a blood sample was taken 4 h after the morning dose of propranolol, and the concentration of propranolol in plasma was determined as previously described [lo].
Results were expressed as the mean values f SD and compared by Student's t-test for independent or dependent data. The 5% probability level was used as a criterion for significance.
Results
There was no difference in clinical status and liver function tests at the two periods of the study ( Table 1) . The heart rate, cardiac output, liver blood flow and the gradient between wedged and free hepatic venous pressures were decreased during the administration of propranolol ( Table 1) .
The volume of distribution of antipyrine was not signifcantly different from that in eight agematched, male control subjects and was not modified by the administration of propranolol ( Table 1 ). The clearance of antipyrine was significantly decreased as compared with that in control subjects but was not further decreased during the administration of propranolol ( Table 1 ). The various findings appeared similar in the five patients who acknowledged drinking until the recent haemorrhage and the three patients who claimed earlier abstinence (not shown).
Discussion
Antipyrine, like most drugs used in humans, has a low hepatic clearance [3] . Its metabolic clearance is not limited by the liver blood flow but depends only on the ability of the liver to oxidize the drug [ll] . The 37% decrease in the clearance of antipyrine previously observed after the administration of propranolol (160 mg daily) in control subjects [4] implies that propranolol decreases the oxidative metabolism of antipyrine in these subjects. Similarly, propranolol has been shown to decrease the metabolism of theophylline [5], another drug with a low hepatic clearance.
In striking contrast, the clearance of antipyrine was not modified during the administration of propranolol in our cirrhotic patients. A first possibility may be that the liver condition did improve between the fust and the second determination of the antipyrine clearance. It is noteworthy, however, that liver-function tests did not improve in these patients ( Table 1) . A second possibility is that propranolol, albeit inhibiting drug metabolism in control subjects, may have little effect on the oxidation of low clearance drugs in cirrhotic patients. F'ropranolol has been shown to be transformed into a reactive metabolite which may lead to the suicide inactivation of cytochrome P-450 [12] . The metabolism of propranolol is markedly reduced in patients with cirrhosis [13] . It is tempting to speculate that, in cirrhotic patients, the decreased metabolism of propranolol may result in a decreased formation of the reactive metabolite and a lesser inactivation of cytochrome P-450.
Further studies are required to assess the mechanism for the differences. The present investigation, however, answers the practical question of what may happen to the metabolism of some low clearance drugs when patients with alcoholic cirrhosis and a recent episode of gastrointestinal bleeding are placed on propranolol therapy.
